Bio-Thera Claims A World First With Chinese Tocilizumab Approval

Actemra/RoActemra Gets NMPA Nod; Offers Option For COVID-19 Treatment

Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.

First Place Gold Medal
Bio-Thera can boast a world first with its tocilizumab approval • Source: Shutterstock

Bio-Thera Solutions has achieved a world first after receiving approval for its BAT1806 biosimilar rival to Actemra/RoActemra from China’s National Medical Products Administration.

“BAT1806 is the first tocilizumab biosimilar approved by the NMPA or any other regulatory agency around the world and has...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.